Up to four follow-up visits (after baseline) were expected for 141 LRRK2-associated parkinsonism cases; the majority completed Year 4 [31 (69%) CSFasynSAA− and 78 (81%) CSFasynSAA+ cases]. The gene discussed is LRRK2; the disease is Parkinson disease.